GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » 12-1 Month Momentum %

Panacea Acquisition II (Panacea Acquisition II) 12-1 Month Momentum % : 4.51% (As of May. 20, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-20), Panacea Acquisition II's 12-1 Month Momentum % is 4.51%.

The industry rank for Panacea Acquisition II's 12-1 Month Momentum % or its related term are showing as below:

PANA's 12-1 Month Momentum % is not ranked
in the Diversified Financial Services industry.
Industry Median: 4.34 vs PANA: 4.51

Competitive Comparison of Panacea Acquisition II's 12-1 Month Momentum %

For the Shell Companies subindustry, Panacea Acquisition II's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Acquisition II's 12-1 Month Momentum % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's 12-1 Month Momentum % falls into.



Panacea Acquisition II  (NAS:PANA) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II  (NAS:PANA) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Panacea Acquisition II 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Acquisition II (Panacea Acquisition II) Business Description

Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines